Given these features, EPO-GEMMs are well poised for use in the evaluation of new therapeutic strategies based on genetic and molecular biomarkers (extending beyond MSI status), a potentially valuable capability as such biomarkers are becoming prevalent in the evolving landscape of gastric adenocarcinoma research and treatment53,54. This evidence concerns the gene EPO and gastric adenocarcinoma.